الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
Endometrial hyperplasia is characterized by proliferation of endometrial glands that may progress to or coexist with endometrial carcinoma. Endometrial hyperplasia relates to excessive cellular proliferation leading to an increased volume of endometrial tissue, where an increase of endometrial glands to stroma is seen at a ratio of greater than 1:1.
Previous studies proved the presence of endometrial stem cells that may have a role in endometrial regeneration and may be responsible for proliferative disorders as in endometrial hyperplasia and endometrial carcinoma. This study was designed to evaluate the potentiality of umbilical cord stem cells using Hematopoietic stem cells with (CD34+) as a marker and Mesenchymal stem cells proliferation in vitro with:
a- Healthy endometrial cells in proliferative phase.
b- Endometrial tissue proved to have endometrial hyperplasia.
as a step towards novel treatment of endometrial hyperplasia.
In this study 40 Umbilical cord blood samples were collected from term delivering women. UCB was collected from the umbilical cord vein with informed consent of the mother. Mononuclear cells were separated and cultured. This study included two groups of patients: first group included 20 normal patients in proliferative phase of menstrual cycle as control group. The second group included 20 patients with endometrial hyperplasia. Endometrial samples from the 40 cases were collected by dilatation and curettage or by curetting endometrium after hysterectomy operations. Then treatment of the normal proliferative and hyperplastic cells with the Mesenchymal
Summary
90
stem cells extract and CD34+ Hematopoietic stem cells extract was done. So 6 groups were formed
Control groups: Group 1: Normal proliferative Endometrium primary culture without addition of stem cells(20 samples) Group 2: Hyperplastic Endometrium primary culture without addition of stem cells(20 samples)
Treated groups
Group 3: Hyperplastic Endometrium primary culture treated with Mesenchymal stem cell extract. (20 samples)
Group 4: Hyperplastic Endometrium primary culture treated with CD34+ Hematopoietic stem cells extract (20 samples) Group 5: Normal proliferative Endometrium primary culture treated with Mesenchymal stem cell extract. (20 samples) Group 6: Normal proliferative Endometrium primary culture treated with CD34+ Hematopoietic stem cells extract (20 samples) The growth kinetics of cells growing in cell culture in all treated groups were carefully monitored and compared to the growth kinetics of both control groups. The growth curve of the six groups all over the entire period of proliferative study revealed that both treated endometrial hyperplastic groups curves showed a lower rate of growth than endometrial hyperplastic curve rate but the mesenchymal group curve was nearer to normal endometrial growth curve. While the treated normal endometrial cells showed no significant difference in their rate of growth compared to normal endometrial control group.
Summary
91
These data revealed that both CD34+ Hematopoietic stem cells extract and mesenchymal stem cells extract both had decreased the rate of growth of endometrial hyperplastic cells culture reaching near to the rate of growth of normal endometrial primary cells culture but the mesenchymal stem cells extract had a higher degree of control making endometrial growth rate nearer to the rate of growth of normal endometrial primary cell culture. These data suggest that umbilical cord blood stem cells may have a role as a novel treatment of endometrial hyperplasia and other proliferative endometrial disorders in the future.